Currently, SGLT2 inhibitors have become a new mainstay in the treatment of T2DM (7), especially in combination with cardiovascular and renal disease, where SGLT2 inhibitors offer important benefits (8, 9). Here, SLC5A2 is linked to type 2 diabetes mellitus.